By Year 
Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer
Liu, Jing; Blake, Stephen J.; Harjunpaa, Heidi; Fairfax, Kirsten A.; Yong, Michelle C. R.; Allen, Stacey; Kohrt, Holbrook E.; Takeda, Kazuyoshi; Smyth, Mark J.; Teng, Michele W. L.
CANCER RESEARCH - 1/09/2016
The effects of targeting both PD-1 and CD96 on tumour immunity, autoimmunity and immune homeostasis
Harjunpaa, H. M.; Blake, S. J.; Liu, J.; Allen, S.; Smyth, M. J.; Teng, M. W. L.
EUROPEAN JOURNAL OF IMMUNOLOGY - 1/08/2016
Checkpoint Immunotherapy : Picking a Winner
Teng, Michele W. L.; Khanna, Rajiv; Smyth, Mark J.
CANCER DISCOVERY - 1/08/2016
Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
Smyth, M.; Blake, S.; Teng, M.; Miles, J.
Cancer Discov - 1/04/2016
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, Mark J.; Ngiow, Shin Foong; Ribas, Antoni; Teng, Michele W. L.
Nature Reviews Clinical Oncology - 1/03/2016
CDF1 Fellowship from the National Health and Medical Research Council of Australia (NHMRC) - 1025552